Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) SVP Richard William Scalzo sold 1,390 shares of the business’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $48,024.50. Following the completion of the sale, the senior vice president now owns 98,568 shares of the company’s stock, valued at $3,405,524.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Dyne Therapeutics Trading Up 0.5 %
DYN opened at $36.59 on Friday. The stock has a market cap of $3.20 billion, a PE ratio of -9.22 and a beta of 1.07. Dyne Therapeutics, Inc. has a 1 year low of $6.40 and a 1 year high of $47.45. The stock’s 50 day simple moving average is $41.07 and its 200-day simple moving average is $33.55.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.02. Equities analysts forecast that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.
Institutional Trading of Dyne Therapeutics
Analyst Ratings Changes
A number of research firms have weighed in on DYN. Guggenheim boosted their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. JPMorgan Chase & Co. increased their target price on Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a research note on Tuesday, July 9th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, September 4th. Morgan Stanley upped their price target on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, Piper Sandler raised their price objective on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $51.40.
Dyne Therapeutics Company Profile
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Featured Articles
- Five stocks we like better than Dyne Therapeutics
- Business Services Stocks Investing
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- How Can Investors Benefit From After-Hours Trading
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.